These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 24163440

  • 1. LLY-2707, a novel nonsteroidal glucocorticoid antagonist that reduces atypical antipsychotic-associated weight gain in rats.
    Sindelar DK, Carson MW, Morin M, Shaw J, Barr RJ, Need A, Alexander-Chacko J, Coghlan M, Gehlert DR.
    J Pharmacol Exp Ther; 2014 Jan; 348(1):192-201. PubMed ID: 24163440
    [Abstract] [Full Text] [Related]

  • 2. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
    Belanoff JK, Blasey CM, Clark RD, Roe RL.
    Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
    Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.
    Behav Brain Res; 2006 Aug 10; 171(2):225-9. PubMed ID: 16782211
    [Abstract] [Full Text] [Related]

  • 4. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
    Belanoff JK, Blasey CM, Clark RD, Roe RL.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):117-20. PubMed ID: 21269600
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.
    Mammi C, Marzolla V, Armani A, Feraco A, Antelmi A, Maslak E, Chlopicki S, Cinti F, Hunt H, Fabbri A, Caprio M.
    Int J Obes (Lond); 2016 Jun 25; 40(6):964-72. PubMed ID: 26830012
    [Abstract] [Full Text] [Related]

  • 7. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.
    Link JT, Sorensen B, Patel J, Grynfarb M, Goos-Nilsson A, Wang J, Fung S, Wilcox D, Zinker B, Nguyen P, Hickman B, Schmidt JM, Swanson S, Tian Z, Reisch TJ, Rotert G, Du J, Lane B, von Geldern TW, Jacobson PB.
    J Med Chem; 2005 Aug 11; 48(16):5295-304. PubMed ID: 16078847
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The selective glucocorticoid receptor antagonist CORT 108297 decreases neuroendocrine stress responses and immobility in the forced swim test.
    Solomon MB, Wulsin AC, Rice T, Wick D, Myers B, McKlveen J, Flak JN, Ulrich-Lai Y, Herman JP.
    Horm Behav; 2014 Apr 11; 65(4):363-71. PubMed ID: 24530653
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
    Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL.
    J Pharmacol Exp Ther; 2005 Dec 11; 315(3):1265-77. PubMed ID: 16141369
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.
    Hunt HJ, Belanoff JK, Walters I, Gourdet B, Thomas J, Barton N, Unitt J, Phillips T, Swift D, Eaton E.
    J Med Chem; 2017 Apr 27; 60(8):3405-3421. PubMed ID: 28368581
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mineralocorticoid receptor.
    Bell MG, Gernert DL, Grese TA, Belvo MD, Borromeo PS, Kelley SA, Kennedy JH, Kolis SP, Lander PA, Richey R, Sharp VS, Stephenson GA, Williams JD, Yu H, Zimmerman KM, Steinberg MI, Jadhav PK.
    J Med Chem; 2007 Dec 27; 50(26):6443-5. PubMed ID: 18038968
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.
    Eur J Pharmacol; 2008 Aug 20; 590(1-3):224-32. PubMed ID: 18573246
    [Abstract] [Full Text] [Related]

  • 20. Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.
    Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H.
    J Pharmacol Exp Ther; 2009 Jul 20; 330(1):179-90. PubMed ID: 19359526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.